ArticleEpilepsia open2025
Global, regional and national burden of epilepsy in adolescents aged 10-19 years from 1990 to 2021: An analysis for the Global Burden of Disease Study 2021.
Article in Epilepsia open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Global trends in epilepsy and the Chinese experience: Epidemiological transitions, underlying mechanisms, and integrated strategies (1990-2021).Neuroprotection (Chichester, England) · 2026Review
- Global, regional and national burden of epilepsy in adolescents aged 10-19 years from 1990 to 2021: An analysis for the Global Burden of Disease Study 2021.Epilepsia open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveEpilepsy, a neurological disorder characterized by recurrent seizures, imposes multidimensional burdens on adolescents aged 10-19 years, including disrupted education, restricted social participation, and diminished socioeconomic prospects. The aim of this study is to analyze global disparities in adolescent epilepsy burden through cross-national comparisons based on global burden of disease (GBD) data, identifying evidence-based strategies from low-burden countries (e.g., tiered care frameworks, stigma-reduction initiatives) to optimize targeted intervention policies.
methodsWe quantified the global burden of adolescent epilepsy (ages 10-19) across 204 countries (1990-2021), measuring deaths, prevalence, and disability-adjusted life years (DALYs), stratified by sex, year, location, and sociodemographic index (SDI), with 95% uncertainty intervals (UIs).
resultsIn 2021, 4.37 (95% UI 2.85-6.21) million adolescents aged 10-19 years lived with epilepsy, corresponding to 338.90 (95% UI 220.72-481.65) per 100 000. The burden increased worldwide, yet exhibited regional disparities: Western Europe, North America, and East Asia demonstrated lower prevalence than sub-Saharan Africa. Age-standardized DALY rates inversely correlated with SDI across regions. The age-standardized DALY rates showed sex-based differences in some regions. SIGNIFICANCE: Global adolescent epilepsy burden exhibited stagnant temporal trends (1990-2021) with pronounced geospatial heterogeneity. However, some countries exhibited paradoxically high DALYs alongside low prevalence, potentially reflecting diagnostic capacity. Case analyses of low-burden exemplars revealed three mitigation pillars: (1) integrated school-based seizure detection systems, (2) decentralized antiepileptic drug distribution networks, and (3) community stigma-reduction campaigns. These evidence-based strategies demonstrated scalable potential for reducing diagnostic delays and sociodemographic disparities, particularly in resource-constrained regions through adaptive implementation of mobile telemedicine and tiered referral protocols. PLAIN LANGUAGE SUMMARY: This study found that epilepsy affects millions of teens worldwide, with higher rates in poorer regions due to limited healthcare and stigma. Countries like China reduced cases through better treatment access and education, while areas like Africa struggled with conflicts and weak health systems. Boys face worse outcomes than girls, partly due to delayed care. Solutions include training local doctors, community education, and affordable medicines to help teens live healthier lives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.